Arizona is currently home to 1777 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
NCT06280235
Recruiting
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their standard therapy throughout the study. Participants are put into 4 groups by chance. 3 of the 4 groups take different doses of BI 1569912. 1 group takes placebo. Placebo tablets looks like BI 1569912 but... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2024
Locations: Southwest Biomedical Research, LLC, Tucson, Arizona
Conditions: Depressive Disorder, Major
Register for Updates
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06203002
Recruiting
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Lexicon Investigational Site (102), Tucson, Arizona
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379
Recruiting
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Research Site, Goodyear, Arizona
Conditions: Breast Cancer
Register for Updates
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet. The purpose of this study is to find out whether people with overweight or obesity who take a medicine called su... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Arizona Liver Health, Mesa, Arizona
Conditions: Obesity
Register for Updates
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria
NCT06072157
Recruiting
This is a Phase 1, randomized, double-blind, placebo-controlled, sequential, single- and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of intravenous (IV) infusions and a single subcutaneous (SC) injection of AK006. The study will be conducted in 4 parts: a single-ascending dose part (Part A) in healthy participants, a multiple-ascending dose part (Part B) in healthy participants with an expanded cohort (Part C) in participants with... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2024
Locations: Site 601-008 (Part C), Scottsdale, Arizona
Conditions: Healthy Participants, Chronic Spontaneous Urticaria
Register for Updates
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: EmVenio Research, Phoenix, Arizona
Conditions: Obesity, Diabetes Mellitus, Type 2
Register for Updates
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540
Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Velocity Clinical Research-Phoenix, Phoenix, Arizona
Conditions: Type 2 Diabetes Mellitus
Register for Updates
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877
Recruiting
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: The University of Arizona Cancer Center, Tucson, Arizona
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States
NCT06026332
Recruiting
Multi-center, prospective non-interventional study to collect data on the early use of ADSTILADRIN in the US. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Ferring Investigational Site, Gilbert, Arizona
Conditions: Bladder Cancer
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
05/13/2024
Locations: Local Institution - 0416, Phoenix, Arizona
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240
Recruiting
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 Period A, participants are placed in 1 of 3 groups, c... Read More
Gender:
All
Ages:
Between 12 years and 63 years
Trial Updated:
05/13/2024
Locations: Advanced Research Associates - Glendale /ID# 259108, Glendale, Arizona
Conditions: Alopecia Areata
Register for Updates
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073
Recruiting
This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: HonorHealth Neurology - Bob Bove Neuroscience Institute, Scottsdale, Arizona
Conditions: Multifocal Motor Neuropathy
Register for Updates